Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04121442 · ClinicalTrials.gov registry record · Phase 1
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
A Phase 1 study, sponsored by Buzzard Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04121442 is a Phase 1 study that has completed, run by Buzzard Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04121442, a Phase 1 study, has completed, sponsored by Buzzard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Isunakinra - a potent Interleukin-1 receptor inhibitor - will be given to patients with solid tumors to determine safety and tolerability of three different doses. Isunakinra will then be combined with a PD-(L)1 inhibitor. Pharmacokinetics and Pharmacodynamic effects of monotherapy treatment as well as the combination will be evaluated.
Interventions
- BIOLOGICAL Isunakinra
- BIOLOGICAL PD-(L)1 Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04121442
The ClinicalTrials.gov registry entry for NCT04121442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Buzzard Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isunakinra is the first listed.
NCT04121442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04121442 about?
NCT04121442 is a clinical study titled "Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors". Isunakinra - a potent Interleukin-1 receptor inhibitor - will be given to patients with solid tumors to determine safety and tolerability of three different doses. Isunakinra will then be combined with a PD-(L)1 inhibitor. Pharmacokinetics and Pharmacodynamic effects of monotherapy treatment as well...
What is the current status of trial NCT04121442?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-09-01. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT04121442?
The interventions under investigation include: Isunakinra (BIOLOGICAL), PD-(L)1 Inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT04121442?
This trial is sponsored by Buzzard Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.